Patents and Industry Updates
2024
Patent-pending work in Engineered Hepatic Tissue Platform for Hepatitis B Virus Disease Modeling and Therapeutic Screening
2025
Patent-pending work in engineered "Integrated Microfluidic Well Plate (h-VIOS system).
PRESS RELEASE
Featured Research: Pioneering the Future of Predictive Toxicology
At SOT 2024, I presented the biological validation of advanced, human-relevant datasets generated by the h-VIOS™ platform. By utilizing state-of-the-art 3D bioprinting to co-culture primary human cells within vascularized architectures, this high-throughput system successfully models complex mechanisms of Drug-Induced Liver Injury (DILI). Driven by automated high-content confocal imaging and AI-powered analytics, our models drastically outperform conventional methods—delivering the human-predictive accuracy needed to safely accelerate preclinical drug screening.
Award-Winning Innovation: Redefining Preclinical Safety at SLAS 2025
I am incredibly proud to be part of the core research that led to Systemic Bio winning the prestigious SLAS 2025 Innovation Award in San Diego. Chosen from an international pool of cutting-edge finalists, our presentation demonstrated how the h-VIOS™ platform uses precisely bioprinted human tissues to capture critical safety risks—specifically for complex therapeutics like antibody-drug conjugates (ADCs)—long before they reach clinical trials. This milestone marks a true paradigm shift in laboratory automation, proving that our vascularized organ-on-a-chip systems can successfully eliminate late-stage failures even when legacy non-human primate studies fail to flag toxicity.
Talks & Presentations
Highlighting global thought leadership and human-relevant scientific knowledge.
The ‘organs-on-chip’ as an alternative to replace animals in drug research
II Integrated Forum of Pathology | Virtual | 2020
Advancing multi-organ microphysiological systems to monitor drug metabolism and systemic toxicity.
Human Visceral Leishmaniasis model based on organs-on-a-chip technology
Brazilian Society of Protozoology (SBPz) | Brazil | 2019
Simultaneously monitoring infectious disease, drug metabolism and immune response in animal-free models.
Assessment of Leishmania's sensitivity to drugs
Biomedical Sciences Institute - USP | Brazil | 2016, 2018, 2019
Advanced class on assessing Leishmania sp. drug sensitivity, showcasing robust in vitro infection models and IC50 analysis to generate decision‑ready data for antiparasitic drug development
Poster Presenter
Conferences
2025
2024
Awards
Walter Colli Award
Brazilian Society of Protozoology | 2018. In vitro human visceral leishmaniasis model based on organs-on-a-chip technology
BMES Annual Meeting
Showcasing natural HBV susceptibility in human hepatocytes using bioengineered tissues.
Society of Toxicology (SOT)
Replicating human liver toxicity in vitro with patent-pending bioprinted methodologies.
Poster Presenter
Poster Presenter
Awards
Best Oral Presentation
SBPz | 2014. Generation of luciferase-expressing Leishmania infantum chagasi: assessing miltefosine efficacy in infected hamsters through intravital microscopy
My Mission
Advancing Human-Relevant Science to Replace Animal Testing
As a Senior Scientist and Project Manager with a background in Veterinary Medicine and a PhD in Translational Research, I bridge biological complexity with engineering precision. My mission is to equip the pharmaceutical industry with high‑fidelity, non‑animal models that generate safer, faster, and more accurate human‑relevant data, closing the gap between traditional research and a future of ethical, precise science.
Relevant Publications
Â
Human-Relevant Bioprinted Liver Model for Drug-Induced Liver Injury Assessment
Systemic Bio White paper (CONFIDENTIAL)Â | 2024
This study demonstrates the superior clinical predictive power of a 3D-bioprinted human liver microphysiological system over traditional 2D monolayers and spheroid models in evaluating Drug-Induced Liver Injury (DILI). By co-culturing primary human hepatocytes and non-parenchymal cells within a biomimetic microsphere scaffold, the platform preserves critical hepatic phenotypes and metabolic biomarkers over extended multi-dose exposure timelines. When tested against a challenging panel of clinically characterized drug pairs, the model accurately identified true hepatotoxics through dose-dependent viability drops, structural degradation, and AI-powered morphological tracking, proving its immense value as a human-relevant alternative method for preclinical safety screening.
Physiological Strategies to Improve Primary Human Hepatocytes Function
In Preparation | 2024
Development of a long-term, highly functional in vitro human liver model that successfully overcomes the rapid dedifferentiation of primary human hepatocytes by combining micropatterned cell architectures with extracellular matrix (ECM) and non-parenchymal celld cues. This synergistic, physiological strategy stabilizes mature hepatic phenotypes, drug metabolism pathways, and structural features for over four weeks using tenfold fewer cells than traditional confluent monolayers, proving highly effective for drug toxicity and enzyme induction screening. Remarkably, the platform demonstrates superior susceptibility to active, long-term Hepatitis B Virus (HBV) replication across multiple cell donors at ultra-low multiplicities of infection without requiring artificial immune suppression, establishing its immense utility as a human-relevant antiviral drug discovery screening tool.
Environ Health Perspect | 2022
Shows that traditional animal-based risk estimates can significantly misrepresent human cancer risk. By focusing on high‑quality human epidemiological evidence, this work refines dose–response relationships and supports more protective, human‑relevant regulatory decisions, reinforcing the need to prioritize human data over animal models in toxicology
Trop Med Int Health |Â 2018
Human clinical trial that evaluates a tamoxifen–meglumine antimoniate combination therapy for cutaneous leishmaniasis, highlighting how drug repurposing and rational combinations can improve treatment strategies for neglected infectious diseases.
Drugs & drug resistance | 2018
Provides a blueprint for biochemical validation required to design high-fidelity MPS.
Journal of Antimicrobial Chemotherapy | 2016
Evaluates synergistic efficacy in translational models for human-relevant safety assessments.
Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool
J Microbiol METHODS | 2013
This study develops a sensitive quantitative method to measure parasite burden in Leishmania (Leishmania) amazonensis infections. By combining bioluminescent parasites with optimized detection, it enables faster, more accurate evaluation of drug efficacy in vivo, improving preclinical decision–making and supporting the shift toward more reliable, human–relevant infectious disease models.